Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Life Sciences Industry Analysis

UpdatedJun 20, 2026
DataAggregated Company Financials
Companies7
  • 7D1.6%
  • 3M8.1%
  • 1Y-9.0%
  • YTD-3.0%

Over the last 7 days, the Life Sciences industry has risen 1.6%, driven by gains from Lonza Group of 1.7%. Meanwhile, Siegfried Holding actually underperformed within the industry, shrinking 7.6% in the last week. However, the industry is down 9.0% over the past year. As for the next few years, earnings are expected to grow by 19% per annum.

Industry Valuation and Performance

Has the Swiss Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 21 Jun 2026CHF 47.4bCHF 10.1bCHF 1.1b36.3x43.4x4.7x
Tue, 19 May 2026CHF 46.0bCHF 10.1bCHF 1.1b37.2x42.1x4.5x
Thu, 16 Apr 2026CHF 50.6bCHF 10.1bCHF 1.1b36.8x44.3x5x
Sat, 14 Mar 2026CHF 45.3bCHF 10.1bCHF 1.3b29.1x35.1x4.5x
Mon, 09 Feb 2026CHF 49.5bCHF 10.1bCHF 1.3b32.4x38.8x4.9x
Wed, 07 Jan 2026CHF 49.6bCHF 10.6bCHF 1.1b30.9x45.1x4.7x
Fri, 05 Dec 2025CHF 49.5bCHF 10.6bCHF 1.1b28.4x45x4.6x
Sun, 02 Nov 2025CHF 50.7bCHF 10.6bCHF 1.1b31x46.1x4.8x
Tue, 30 Sep 2025CHF 48.2bCHF 10.6bCHF 1.1b30.9x43.9x4.5x
Thu, 28 Aug 2025CHF 53.5bCHF 10.6bCHF 1.1b34.9x48.6x5x
Sat, 26 Jul 2025CHF 54.6bCHF 10.6bCHF 1.1b37.5x48x5.1x
Mon, 23 Jun 2025CHF 52.5bCHF 10.1bCHF 1.0b33.3x50.6x5.2x
Wed, 21 May 2025CHF 52.6bCHF 10.1bCHF 1.0b32.9x50.7x5.2x
Fri, 18 Apr 2025CHF 49.4bCHF 10.1bCHF 1.0b28.1x48.2x4.9x
Sun, 16 Mar 2025CHF 52.1bCHF 10.1bCHF 1.0b33.2x51.2x5.2x
Tue, 11 Feb 2025CHF 57.7bCHF 10.1bCHF 1.0b36x57.4x5.7x
Thu, 09 Jan 2025CHF 54.6bCHF 10.2bCHF 943.4m36.2x57.9x5.4x
Sat, 07 Dec 2024CHF 52.6bCHF 10.2bCHF 943.8m39.5x55.8x5.2x
Mon, 04 Nov 2024CHF 55.6bCHF 10.2bCHF 943.3m42.2x58.9x5.4x
Wed, 02 Oct 2024CHF 55.3bCHF 10.2bCHF 943.5m42.2x58.6x5.4x
Fri, 30 Aug 2024CHF 57.7bCHF 10.2bCHF 937.1m45.6x61.6x5.7x
Sun, 28 Jul 2024CHF 59.4bCHF 10.2bCHF 923.2m45.3x64.3x5.8x
Tue, 25 Jun 2024CHF 52.0bCHF 10.3bCHF 1.0b44.2x51.9x5.1x
Thu, 23 May 2024CHF 54.7bCHF 10.3bCHF 1.0b45x54.7x5.3x
Sat, 20 Apr 2024CHF 53.5bCHF 10.3bCHF 1.0b43x53.3x5.2x
Mon, 18 Mar 2024CHF 52.8bCHF 10.2bCHF 1.0b44.7x52.6x5.2x
Wed, 14 Feb 2024CHF 48.2bCHF 10.2bCHF 1.0b43.4x47.3x4.7x
Fri, 12 Jan 2024CHF 42.5bCHF 9.8bCHF 1.5b32x28.5x4.4x
Sun, 10 Dec 2023CHF 39.3bCHF 9.8bCHF 1.5b29.9x26.3x4x
Tue, 07 Nov 2023CHF 39.1bCHF 9.8bCHF 1.5b27.7x26.2x4x
Thu, 05 Oct 2023CHF 46.0bCHF 9.8bCHF 1.5b31.4x30.8x4.7x
Sat, 02 Sep 2023CHF 53.4bCHF 9.8bCHF 1.5b36.9x35.8x5.5x
Mon, 31 Jul 2023CHF 53.8bCHF 9.8bCHF 1.5b36.8x34.8x5.5x
Wed, 28 Jun 2023CHF 54.0bCHF 9.7bCHF 1.6b33.8x33.1x5.6x
Price to Earnings Ratio

33.1x


Total Market Cap: CHF 54.0bTotal Earnings: CHF 1.6bTotal Revenue: CHF 9.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Life Sciences Industry Price to Earnings3Y Average 46.4x202420252026
Current Industry PE
  • Investors are pessimistic on the Swiss Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 43.4x which is lower than its 3-year average PE of 46.4x.
  • The industry is trading close to its 3-year average PS ratio of 5.0x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have declined 13% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market0.72%
Healthcare-1.85%
Life Sciences1.56%
Clinical Research and Equipment1.56%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LONN Lonza GroupCHF 498.701.7%
+CHF 586.7m		-11.0%PE38.3x
PPGN PolyPeptide GroupCHF 39.3516.2%
+CHF 181.5m		98.1%PS3.6x
BANB Bachem HoldingCHF 67.952.9%
+CHF 142.4m		16.6%PE34.2x
TECN Tecan GroupCHF 151.702.8%
+CHF 52.6m		-5.4%PS2.2x
SKAN SKAN GroupCHF 49.300.3%
+CHF 3.4m		-32.0%PE68.1x

Latest News

SFZN
CHF 67.95
Siegfried Holding
7D
-7.6%
1Y
-28.1%
Analysis Article • Jun 19

Siegfried Holding (SWX:SFZN) Stock Could Be 35.5% Undervalued After New API Facility Opens

Siegfried Holding (SWX:SFZN) has opened a new large scale API manufacturing facility in Minden, Germany, adding 100 m³ of reactor capacity and expanding its role as a global CDMO for small molecule drug substances. See our latest analysis for Siegfried Holding. Despite Siegfried Holding’s new API facility pointing to expanded capacity and customer demand, recent momentum has been weak, with the share price down 16.82% over 30 days and the 1 year total shareholder return down 28.36%,...
SKAN
CHF 49.30
SKAN Group
7D
0.3%
1Y
-32.0%
Narrative Update • Jun 17

SKAN: Dividend Payouts And Order Backlog Will Support Future Returns

Analysts have kept their SKAN Group price target steady at CHF 62.50, noting that small adjustments to the discount rate and future P/E assumptions did not materially change their overall valuation view. What’s in the News for SKAN Group The Board of Directors of SKAN Group AG plans to propose a dividend of CHF 0.22 per share to the Annual General Meeting on May 7, 2026, corresponding to a 30% payout ratio.
LONN
CHF 498.70
Lonza Group
7D
1.7%
1Y
-11.0%
TECN
CHF 151.70
Tecan Group
7D
2.8%
1Y
-5.4%
Narrative Update • Jun 14

TECN: Reset CHF 205 Goal Will Support Future Earnings Re Rating

Analysts have reduced their price target for Tecan Group from CHF 335.08 to CHF 205.00, citing updated assumptions for revenue growth, profit margins and future P/E multiples, along with recent Street research cuts from CHF 10 and CHF 1. Analyst Commentary Recent Street research has focused on recalibrating Tecan Group’s valuation framework, with price targets adjusted to reflect updated views on revenue growth, margins and P/E multiples.
BANB
CHF 67.95
Bachem Holding
7D
2.9%
1Y
16.6%
Narrative Update • Jun 05

BANB: Future Upside Will Rely On Executing Margin Assumptions And Higher P E Framework

Analysts have raised their CHF price targets on Bachem Holding, including recent CHF 5 and CHF 5 increases from two major banks, reflecting updated views on growth, margins, and future P/E assumptions. Analyst Commentary Bullish analysts are signaling a constructive view on Bachem Holding, pointing to updated price targets that reflect their latest assumptions on growth, margins, and valuation.
PPGN
CHF 39.35
PolyPeptide Group
7D
16.2%
1Y
98.1%
XLS
CHF 25.20
Xlife Sciences
7D
2.0%
1Y
28.2%